


Moderna's Respiratory Vaccines: Pediatric RSV + hMPV vaccine (mRNA-1365)

Last program update: September 9, 2021



Modality	Program	ID #	Preclinical development	Phase 1	Phase 2	Phase 3	Commercial	Moderna rights
Adults  Prophylactic vaccines	COVID-19 vaccine	mRNA-1273	[Progress bar]					Worldwide
		mRNA-1273.351	Beta variant	[Progress bar]				Worldwide
		mRNA-1273.617	Delta variant	[Progress bar]				Worldwide
		mRNA-1273.211	Beta variant + wild-type	[Progress bar]				Worldwide
		mRNA-1273.213	Beta + Delta variant	[Progress bar]				Worldwide
		mRNA-1283	Next generation (2-5 °C)	[Progress bar]				Worldwide
	Flu vaccine	mRNA-1010	Phase 1/2	[Progress bar]	Phase 2/3 prep			Worldwide
		mRNA-1020	[Progress bar]					Worldwide
		mRNA-1030	[Progress bar]					Worldwide
	COVID + Flu vaccine	mRNA-1073	mRNA-1273 + mRNA-1010	[Progress bar]				Worldwide
Older adults RSV vaccine	mRNA-1345	[Progress bar]	Phase 2/3 prep				Worldwide	
Adolescents & Pediatrics	COVID-19 vaccine (adolescents)	mRNA-1273	TeenCOVE	[Progress bar]				Worldwide
	COVID-19 vaccine (pediatrics)	mRNA-1273	KidCOVE	[Progress bar]				Worldwide
	Pediatric RSV vaccine	mRNA-1345	Phase 1b	[Progress bar]				Worldwide
	Pediatric hMPV + PIV3 vaccine	mRNA-1653	[Progress bar]					Worldwide
	Pediatric RSV + hMPV vaccine	mRNA-1365	[Progress bar]					Worldwide

Announcing two new combination vaccines are progressing towards the clinic


COVID/Flu
mRNA-1073



RSV/hMPV
mRNA-1365



mRNA-1365 encodes for a RSV prefusion F glycoprotein and a hMPV F protein



Cytosol

Endoplasmic reticulum

Nucleus

We are developing combination vaccines against the respiratory viruses with greatest public health impact

Developing vaccines against respiratory viruses with greatest public health impact



INFLUENZA



SARS-CoV-2



RSV



hMPV



PIV3



More viruses...

Combination vaccines may lead to:

- Higher compliance
- Better uptake
- Larger benefit to healthcare system

Clinical trials ongoing



hMPV/PIV3

Preparing for clinical trials



COVID/Flu



Pediatric RSV/hMPV

In research



COVID/Flu/RSV



More combinations...

Forward-looking statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended including, but not limited to, statements concerning potential development candidate applications, development candidate activities, preclinical and clinical studies, regulatory submissions and approvals, risk management and estimates and forward-looking projections with respect to Moderna or its anticipated future performance or events. In some cases, forward-looking statements can be identified by terminology such as “may,” “should,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this presentation are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties and other factors include, among others: preclinical and clinical development is lengthy and uncertain, especially for a new category of medicines such as mRNA, and therefore Moderna’s preclinical programs or development candidates may be delayed, terminated, or may never advance to or in the clinic; no mRNA drug has been approved in this new potential category of medicines, and may never be approved; mRNA drug development has substantial clinical development and regulatory risks due to the novel and unprecedented nature of this new category of medicines; and those described in Moderna’s most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements in this presentation in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date hereof.